---
layout: default
title: Alfuzosina
parent: 僅模型預測 (L5)
nav_order: 18
evidence_level: L5
indication_count: 0
---

# Alfuzosina
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosina: Drug Repurposing Evaluation Report

## One-Sentence Summary

Alfuzosina (Alfuzosin) is an alpha-1 adrenergic receptor antagonist historically used for benign prostatic hyperplasia (BPH). Currently, the TxGNN model has **no predicted new indications** for this drug, and there are **no clinical trials** or **publications** associated with a repurposing direction. Significant data gaps remain, including mechanism of action details and regulatory safety information.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no approved licenses found in Taiwan) |
| Predicted New Indication | None — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No model prediction or supporting studies) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on general pharmacological knowledge, Alfuzosina (Alfuzosin) is a selective alpha-1 adrenergic receptor antagonist. It works by relaxing smooth muscle in the prostate and bladder neck, thereby improving urinary flow in patients with benign prostatic hyperplasia (BPH). It is not classified as an antineoplastic agent.

However, the TxGNN model has not generated any predicted new indications for Alfuzosina at this time. Without a predicted indication, no mechanism-based rationale for repurposing can be assessed. The absence of a prediction may reflect insufficient representation of Alfuzosina in the knowledge graph, or it may indicate that the model did not identify a statistically meaningful disease association above its threshold.

Additionally, Alfuzosina has no approved licenses in Taiwan (TFDA), meaning there is no local regulatory footprint from which to derive approved indication text or safety labeling. This further limits the ability to conduct a meaningful repurposing evaluation.

## Clinical Trial Evidence

Currently no related clinical trials registered for any repurposing indication.

## Literature Evidence

Currently no related literature available for any repurposing indication.

## Taiwan Market Information

Alfuzosina has **no approved licenses** registered with the TFDA. The drug is currently **not marketed** in Taiwan.

## Safety Considerations

> Please refer to the package insert for safety information.
>
> All safety fields (key warnings, contraindications, and drug-drug interactions) returned as data gaps or not found. The TFDA package insert query returned 1 result, but structured safety data was not extracted. A manual review of the source package insert is recommended before any clinical decision-making.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications exist for Alfuzosina, and the drug is not currently marketed in Taiwan. There is insufficient data to evaluate any repurposing hypothesis at this time.

**To proceed, the following is needed:**
- **TxGNN model re-run**: Ensure Alfuzosina is properly represented in the knowledge graph and re-run predictions
- **DrugBank ID resolution**: The DrugBank ID is missing (`null`); resolving this (likely **DB00346**) would unlock MOA, target, and pathway data
- **TFDA package insert parsing**: Extract structured safety data (warnings, contraindications) from the package insert PDF identified in the query log
- **MOA data retrieval**: Query DrugBank API with the resolved ID to fill the mechanism of action data gap (DG002, severity: High)
- **Regulatory safety data**: Address blocking data gap DG001 (severity: Blocking) — retrieve and parse TFDA labeling information before any safety screening can proceed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

